Howard Rosen to its Executive Management Team as VP Marketing and Business Development at Intact Vascular

My Subscriptions

Payment Confirmation

Transaction Failed

Your transaction failed, please try again or contact site support.

Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that Howard Rosen has joined its executive management team as Vice President of Marketing and Business Development. In this position, Mr. Rosen will lead the company’s efforts to prepare for commercialization of its Tack Endovascular System® for the repair of dissections following peripheral artery angioplasty.

“Howard brings deep experience in both upstream and downstream marketing, as well as first-hand knowledge of the peripheral vascular marketplace and our customers,” said Bruce J. Shook, Intact Vascular’s President and CEO. “Howard is a welcome addition to our team as we move through the Pre-Market Approval (PMA) application process and toward market introduction of our products,” Shook continued.

Prior to joining Intact Vascular, Mr. Rosen’s career included twenty-one years at Boston Scientific Corporation (NYSE: BSX), where he began his career as a sales representative and rose through the marketing ranks to hold positions of increasing responsibility in the peripheral vascular interventions and cardiovascular businesses. Mr. Rosen most recently served as Vice President of the Cell Processing Franchise at the Haemonetics Corporation (NYSE: HAE).

“Intact Vascular has created a novel solution to the widespread problem of dissections following angioplasty, and the company has made a significant investment in clinical research. I am excited to build on that strong foundation and bring this important technology to clinicians and their patients,” said Mr. Rosen.

Intact Vascular is sponsoring three clinical trials to evaluate its Tack Endovascular System: TOBA II, TOBA II BTK and TOBA III. TOBA II is investigating the combination of the Tack® device, with both plain and drug-coated balloon angioplasty in the arteries above the knee. TOBA II BTK is investigating the combination of the Tack device with plain balloon angioplasty in the arteries below the knee. TOBA III is currently underway in Europe and is investigating the combination of the Tack Endovascular System with drug-coated balloon angioplasty. Visit http://www.intactvascular.com/actively-enrolling for more information on Intact Vascular’s robust clinical development program in the endovascular treatment of peripheral arterial disease.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.